Tirzepatide

Dual GIP and GLP-1 receptor agonist.

Approved dual GIP/GLP-1 agonist. Large phase 3 programme.

The community's own word for what tirzepatide does is "food noise" - the constant background negotiation about eating - and the most consistently reported thing is that it goes quiet. People describe deciding not to finish a plate without it feeling like a decision. That is the effect people come back to describe, more than the number on the scale.

The practical conventions are unusually consistent. Titrate slower than the schedule allows: the people who report a miserable first month are nearly always the ones who moved up on the calendar rather than on how they felt, and the people who did well routinely say they stayed at a lower step longer and landed lower overall than they expected to need. Eat protein first, because appetite is now a limited budget and it gets spent on whatever is in front of you. Constipation is the complaint that outlasts the nausea, and fibre and water are what the community reaches for. Sulphur burps come up constantly and are treated as a sign of eating too much fat in one sitting.

Muscle loss is the theme experienced users raise with newer ones unprompted - resistance training and protein are described as non-negotiable rather than optional, and the regret people voice at the far end is usually about that rather than about the drug. A reproductive signal shows up in community reports that is not in the labelling: intermenstrual bleeding, heavier periods and irregular cycles, each at roughly one percent of reports. Worth knowing if you are a woman running this.